Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon α by differentiation-inducing agents

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 546-554

  Goto, I ^a   Yamamoto Yamaguchi, Y ^a   Honma, Y ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Biological response modifier; Differentiation inducer; Interferon; Lung carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; BUTYRIC ACID; DIFFERENTIATION INDUCING FACTOR; DIMETHYL SULFOXIDE; HEXAMETHYLENEBISACETAMIDE; INTERFERON RECEPTOR; PHENYLACETIC ACID; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MATURATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029737436     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.399     Document Type: Article

References (44)

1. AGARWALA SS AND KIRKWOOD JM. (1994). Interferons in the therapy of solid tumors. Oncology, 51, 129-136.
2. ARNOLD A, AYOUB J, DOUGLAS L, HOOGENDOORN P, SKIGLEY L, GELMON K, HIRSH V AND EISENHAUER E. (1994). Phase II trial of 13-cis-retinoic acid plus interferonα in non-small-cell lung cancer. J. Natl Cancer Inst., 86, 306-309.
3. AZUMA A, YAMANO Y, YOSHIMURA A, HIBINO T, HISHIDA T, YAGITA H, OKUMARA K, SEYA T, KANNAGI R, SHIBUYA M AND KUDOH S. (1995). Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins. Scand. J. Immunol., 42, 202-208.
4. DALE TC, ROSEN JM, GUILLE MJ, LEWIN AR, PORTER AGC, KERR IM AND STARK GR. (1989). Overlapping sites for constitutive and induced DNA binding factors involved in interferon-stimulated transcription. EMBO J.. 8, 831-839.
5. DEGOS L. (1990). Differentiating agents in the treatment of leukemia and myelodysplastic syndromes. Leukemia Res., 14, 731-733.
6. DIGNAM JD, LEBOVITZ RM AND ROEDER PG. (1983). Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res., 11, 1475-1489.
7. DONNADIEU N, PAESMANS M AND SOULIER JP. (1991). Chemotherapy of non-small lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer, 7, 243-252.
8. EDELSON JD, SHANNON JM AND MASON RJ. (1988). Alkaline phosphatase: a marker of alveolar type II cell differentiation. Am. Rev. Respir. Dis., 138, 1268-1275.
9. GIARD DJ, AARONSON SA, TODARO GJ, ARNSTEIN P, KERSEY JH, DOSIK H AND PARKS WO. (1972). In vitro cultivation of human tumors: establishment of cell lines from a series of solid tumors. J. Natl Cancer Inst., 51, 1417-1423.
10. GINSBERG RJ, KRIS MG AND ARMSTRONG J. (1993). Cancer of the lung. In: Cancer: Principles and Practice of Oncology, 4th edn, Devota VT, Hellman S and Rosenberg SA. (eds), pp. 673-772, J.B. Lippincott: Philadelphia.
11. GOTO I, HOZUMI M AND HONMA Y. (1994). Selective effect of O-alkyl lysophospholipids on the growth of a human lung giant cell carcinoma cell line. Anticancer Res., 14, 357-362.
12. GUCHELAAR HJ, TIMMER-BOSSCHA H, DAM-MEIRING A, UGES DRA, OOSTERHUIS JW AND DEVRIES EGE. (1993). Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int. J. Cancer, 55, 442-447.
13. HANAI N, ISHIHARA T, UCHINO F, IMADA N, FUJIHARA S AND IKEGAMI J. (1979). Effects of dimethyl sulfoxide and colchicine on the resorption of experimental amyloid. Virchows Arch. A Path. Anat. Histol., 384, 45-52.
14. HIRAKI S, MIYAI M, SETO T, TAMURA T, WATANABE Y, OZAWA S, IKEDA H, NAKATA Y, OHNOSHI T AND KIMURA I. (1982). Establishment of human continuous cell lines from squamous cell, adeno- and small cell carcinoma of the lung and the results of hetero-transplantation. Haigan, 22, 53-58.
15. HONMA Y, ONOZUKA Y, OKABE-KADO J, KASUKABE T AND HOZUMI M. (1991). Hemin enhances the sensitivity of erythroleukemia cells to 1-β-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of cytidine deaminase activity. Cancer Res., 51, 4535-4538.
16. HOZUMI M. (1983). Fundamentals of chemotherapy of myeloid leukemia by induction of leukemia cell differentiation. Adv. Cancer Res., 38, 121-169.
17. HUANG ME, YE Y, CHEN SR, CHAI JR, LU JX, ZHOA L, GU LJ AND WANG ZI. (1988). Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 72, 567-572.
18. ISOBE T AND OSSERMAN EF. (1976). Effects of dimethyl sulfoxide (DMSO) on Bence Jones protein, amyloid fibrils and casein-induced amyloidosis. In: Amyloidosis, O Wegelius, A Pasternach (eds) pp. 247-257, Academic Press: New York.
19. IWASAKI T, HAMANO T, AIZAWA K, KOBAYASHI K AND KAKISHITA E. (1994). A case of pulmonary amyloidosis associated with multiple myeloma successfully treated with dimethyl sulfoxide. Acta Haematol., 91, 91-94.
20. KASAHARA K, FUJIWARA Y AND NISHIO K. (1991). Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res., 51, 3237-3242.
21. KESSLER DS, PINE R, PFEFFER LM, LEVY DE AND DARNELL JE (1988). Cells resistant to interferon are defective in activation of a promoter-binding factor. EMBO J., 7, 3779-3783.
22. KLASTERSKY J, SCULIER JP, NICAISE C, WEERTS D, MAIRESSE M, LIBERT P, ROCMANS P, MICHEL J AND FERREMANS W. (1983). Combination chemotherapy with cisplatin etoposide and vindesine in non-small cell lung carcinoma. Cancer Treat. Rep., 67, 727-730.
23. KOYAMA H AND ONO T. (1976). Induction by short-chain fatty acids of alkaline phosphatase activity in cultured mammalian cells. J. Cell. Phys., 88, 49-56.
24. LEVY DE, KESSLER DS, PINE R AND DARNELL JE. (1988). Interferon-induced nuclear factors that hind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev., 2, 383-393.
25. LEVY DE, KESSLER DS, PINE R AND DARNELL JE. (1989). Cytoplasmic activation of ISGF3, the positive regulator of interferon α-stimulated transcription, reconstituted in vitro. Genes Dev., 3, 1362-1371.
26. LIPPMAN SM, KAVANAGH JJ, PAREDES-ESPINOZA M, DELIGADILLO-MADRUENO F, PAREDES-CASILLAS P, HONG WK, HOLDENER E AND KRAKOFF IH. (1992a). 13-cis-Retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J. Natl Cancer Inst., 84, 241-245.
27. LIPPMAN SM, PARKINSON DR, ITRI LM, WEBER RS, SCHANTZ SP, OTA DM, SCHUSTERMAN MA, KRAKOFF IH, GUTTERMAN JU AND HONG WK. (1992b). 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J. Natl Cancer Inst., 84, 235-241.
28. LOETHER PJ AND EINHORN LH. (1984). Cisplatin. Ann. Intern. Med., 100, 704-713.
29. MCCORMICK C, FRESHNEY RI AND SPEIRS V. (1995). Activity of interferon α, interleukin 6 and insulin in the regulation of differentiation in A549 alveolar carcinoma cells. Br. J. Cancer, 1, 232-239.
30. MARTYRE M-C AND WIETZERBIN J. (1994). Characterization of specific functional receptors for HuIFN-α on a human megakaryocytic cell line (Dami): expression related to differentiation. Br. J. Haematol., 86, 244-252.
31. OHNO R, YOSHIDA H, FUKUTANI H, NAOE T, OHSHIMA T, KYO T, ENDOH N, FUJIMOTO T, KOBAYASHI T, HIRAOKA A, MIZOGUCHI H, KODERA Y, SUZUKI H, HIRANO M, AKIYAMA H, AOKI N, SHINDO H AND YOKOMAKU S. (1993). Multinstitutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia, 7, 1772-1727.
32. OHTANI T, YAMADA R, TAIRA O, OOHMA M, TSUJI K AND HAYATA Y. (1976). Immune response in one case of advanced lung cancer. Haigan, 16, 67-71.
33. OKABE-KADO J, HAYASHI M, HONMA Y AND HOZUMI M. (1986). Enhancement by hemin on the sensitivity of K562 human leukemic cells to 1-β-D-arabinofuranosylcytosine. Cancer Res., 46, 1239-1243.
34. OKABE-KADO J, HAYASHI M, HONMA Y, HOZUMI M AND TSURUO T. (1991). Inhibition by erythroid differentiation factor (activin A) of p-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells. Cancer Res., 51, 2582-2586.
35. REUBEN RC, WIFE RL, BRESLOW R, RIFKIND RA AND MARKS PA. (1976). A new group of protein inducers of differentiation in murine erythroleukemia cells. Proc. Natl Acad. Sci. USA, 73, 862-866.
36. RUTHERFORD MN, HANNIGAN GE AND WILLIAMS BRG. (1988). Interferon-induced binding of nuclear factors to promoter elements of the 2-5A synthetase gene. EMBO J., 7, 751-759.
37. SAKIYAMA S, NAKAMURA Y AND YASUDA S. (1986). Expression of epidermal growth factor receptor gene in cultured human lung cancer cells. Jpn. J. Cancer Res., 77, 965-969.
38. SAMID D, SHACK S AND SHERMAN LT. (1992). Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52, 1988-1992.
39. TERASAKI T, SHIMOSATO Y, NAKAJIMA T, TSUMURAYA M, MORINAGA S, HIROHASHI S, YAMAGOCHI K, KATO K, ICHINOSE H AND NAGATSU T. (1986). Changes in cell characteristics due to culture conditions in cell lines from human small cell lung cancer. Jpn. J. Clin. Oncol., 16, 203-212.
40. WORRALL PM. (1982). Single-dose ifosfamide: efficacy studies in non small lung cancer. Semin. Oncol., 9 (Suppl. 1), 56-60.
41. XU B, GRANDER D, SANGFELT O AND EINHORN S. (1994). Primary leukemia cells resistant to α-interferon in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3. Blood, 84, 1942-1949.
42. YAMADA T, HIROHASHI S AND SHIMOSATO Y. (1985). Giant carcinomas of the lung producing colony-stimulating factor in vitro and in vivo. Jpn. J. Cancer Res., 76, 967-976.
43. YOSHIOKA S. (1989). Studies on thiol protease inhibitor isolated from human lung cancer cell lines. Hiroshima J. Med. Sci., 37, 199-215.
44. YOUNG CW, FANUCCHI MP, WALSH D, BALTZKR L, YALDAEI S, STEVENS Y-W, GORDON C, TONG W, RIFKIND RA AND MARKS PA. (1988). Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day countinous intravenous infusion at twenty-eight-day intervals. Cancer Res., 8, 7304-7309.